Search results for "COVID-19 Vaccines"

showing 10 items of 55 documents

SARS-CoV-2 vaccine response and rate of breakthrough infection in patients with hematological disorders

2022

Abstract Background The clinical efficacy of SARS-CoV-2 vaccines according to antibody response in immunosuppressed patients such as hematological patients has not yet been established. Patients and methods A prospective multicenter registry-based cohort study conducted from December 2020 to December 2021 by the Spanish transplant and cell therapy group was used to analyze the relationship of antibody response at 3–6 weeks after full vaccination (2 doses) with breakthrough SARS-CoV-2 infection in 1394 patients with hematological disorders. Results At a median follow-up of 165 days after complete immunization, 37 out of 1394 (2.6%) developed breakthrough SARS-CoV-2 infection at median of 77 …

*Pfizer-BioNTech BNT162b2Cancer ResearchCOVID-19 Vaccines*Hematological malignanciesAutologous stem cell transplantationAntibodies ViralBreakthrough SARS-CoV-2 infectionModerna mRNA-1273Cohort StudiesHematological malignancies*Moderna mRNA-1273Correlates of protection*VaccineHumansProspective StudiesVacunacióPfizer-BioNTech BNT162b2Molecular BiologyBNT162 Vaccine*Immunocompromised patients*Correlates of protectionSARS-CoV-2VaccinationHematologic diseasesCOVID-19Hematology*Breakthrough SARS-CoV-2 infectionHematologic DiseasesSARS-CoV-2 vaccinesAllogeneic stem cell transplantationVirusOncologyMalalties hematològiquesImmunocompromised patients*SARS-CoV-2 vaccines*Autologous stem cell transplantation*COVID-19Vaccine*Allogeneic stem cell transplantationJournal of Hematology & Oncology
researchProduct

One year into the pandemic: Short-term evolution of SARS-CoV-2 and emergence of new lineages.

2021

The COVID-19 pandemic was officially declared on March 11th, 2020. Since the very beginning, the spread of the virus has been tracked nearly in real-time by worldwide genome sequencing efforts. As of March 2021, more than 830,000 SARS-CoV-2 genomes have been uploaded in GISAID and this wealth of data allowed researchers to study the evolution of SARS-CoV-2 during this first pandemic year. In parallel, nomenclatures systems, often with poor consistency among each other, have been developed to designate emerging viral lineages. Despite general fears that the virus might mutate to become more virulent or transmissible, SARS-CoV-2 genetic diversity has remained relatively low during the first ~…

0301 basic medicineMicrobiology (medical)COVID-19 VaccinesSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)030106 microbiologyReviewBiologyMicrobiologyGenomeVirusDNA sequencing03 medical and health sciencesVACCINESGenetic variationPandemicGeneticsHumansLineagesMolecular BiologyEcology Evolution Behavior and SystematicsTransmission (medicine)SARS-CoV-2VaccinationVariantsGenetic VariationCOVID-19Biological EvolutionVaccination030104 developmental biologyInfectious DiseasesEvolutionary biologyDiagnostic tests
researchProduct

Towards a European strategy to address the COVID-19 pandemic

2021

2019-20 coronavirus outbreakCOVID-19 VaccinesCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Physical DistancingMass Vaccination03 medical and health sciences0302 clinical medicinePolitical scienceCorrespondencePandemicHumans030212 general & internal medicinePandemicsHealth policy030304 developmental biology0303 health sciencesSARS-CoV-2Health PolicyIncidenceIncidence (epidemiology)COVID-19General MedicineVirology3. Good healthEuropeMass vaccinationHuman medicineThe Lancet
researchProduct

GRAd-COV2, a gorilla adenovirus-based candidate vaccine against COVID-19, is safe and immunogenic in younger and older adults

2022

International audience; Safe and effective vaccines against coronavirus disease 2019 (COVID-19) are essential for ending the ongoing pandemic. Although impressive progress has been made with several COVID-19 vaccines already approved, it is clear that those developed so far cannot meet the global vaccine demand alone. We describe a COVID-19 vaccine based on a replication-defective gorilla adenovirus expressing the stabilized prefusion severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein named GRAd-COV2. We assessed the safety and immunogenicity of a single-dose regimen of this vaccine in healthy younger and older adults to select the appropriate dose for each age group…

2019-20 coronavirus outbreakCOVID-19 VaccinesSettore BIO/06Coronavirus disease 2019 (COVID-19)COVID-19 VaccineSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)GorillaAdenoviridaeAdenovirus Vaccinesbiology.animalPandemicAnimalsHumansMedicineMESH: COVID-19MESH: AnimalsMESH: SARS-CoV-2AgedMESH: Adenovirus VaccinesMESH: AgedGorilla gorilla[SDV.MHEP] Life Sciences [q-bio]/Human health and pathologyMESH: HumansbiologyAnimalSARS-CoV-2business.industryMESH: Gorilla gorillaCOVID-19MESH: AdenoviridaeGeneral MedicineVirologyAdenovirus VaccineMESH: COVID-19 Vaccinesbusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyHuman
researchProduct

Attitudes of Healthcare Personnel towards Vaccinations before and during the COVID-19 Pandemic

2021

Vaccines constitute highly effective tools for controlling and eliminating vaccine-preventable diseases (VPDs) and are assessed to avert between two to three million deaths per year globally. Healthcare personnel (HCP) constitute a priority group for several vaccinations. However, studies indicate significant rates of vaccine hesitancy among them and, therefore, of acceptance of vaccination recommendations. This cross-sectional study was conducted in a university hospital in Southern Italy to assess the knowledge and attitudes of HCP about VPDs before and during the COVID-19 pandemic, estimate their intention to get vaccinated against COVID-19, and search for determinants that may influence…

2019-20 coronavirus outbreakHealth Knowledge Attitudes PracticeknowledgeCOVID-19 VaccinesCoronavirus disease 2019 (COVID-19)Cross-sectional studyOccupational riskHealth Toxicology and MutagenesisCOVID-19 Vaccinelcsh:MedicineArticle03 medical and health sciences0302 clinical medicineSurveys and QuestionnairesEnvironmental healthHealth carePandemicoccupational riskHumansMedicineSurveys and Questionnaire030212 general & internal medicinePandemicsCross-Sectional Studie0303 health sciencesattitudes030306 microbiologybusiness.industrySARS-CoV-2lcsh:RPublic Health Environmental and Occupational HealthCOVID-19University hospitalvaccinationVaccinationCross-Sectional StudiesAttitudeItalyPandemics.vaccine hesitancybusinessHumanhealthcare personnelInternational Journal of Environmental Research and Public Health
researchProduct

Racing for a SARS‐CoV‐2 vaccine

2021

Interview with EMBO Members Özlem Türeci and Uğur Şahin, BioNTech, conducted by science journalist Kai Kupferschmidt.

2019-20 coronavirus outbreakMedicine (General)COVID-19 VaccinesCoronavirus disease 2019 (COVID-19)SARS-CoV-2business.industrySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)ImmunologyCOVID-19QH426-470VirologyR5-920GeneticsHumansMolecular MedicineMedicineInterviewbusinessEMBO Molecular Medicine
researchProduct

Acceptance of SARS-CoV-2 Vaccination Among a Cohort of IBD Patients From Southern Italy: A Cross-Sectional Survey

2021

2019-20 coronavirus outbreakmedicine.medical_specialtyCOVID-19 VaccinesCoronavirus disease 2019 (COVID-19)Cross-sectional studySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Directive CounselingInternal medicineHumansImmunology and AllergyMedicineFamilyPhysician's RoleLetter to the EditorAcademicSubjects/MED00260Ibdjnl/1SARS-CoV-2business.industryGastroenterologistsVaccinationAge FactorsGastroenterologyCOVID-19Inflammatory Bowel DiseasesPatient Acceptance of Health CareInflammatory Bowel DiseasesVaccinationItalyInfluenza VaccinesCohortbusinessAttitude to HealthInflammatory Bowel Diseases
researchProduct

Urology practice during the COVID-19 vaccination campaign

2021

Introduction: The current scenario of the COVID-19 pandemic is significantly different from that of the first, emergency phase. Several countries in the world are experiencing a second, or even a third, wave of contagion, while awaiting the effects of mass vaccination campaigns. The aim of this report was to provide an update of previously released recommendations on prioritization and restructuring of urological activities. Methods: A large group of Italian urologists directly involved in the reorganization of their urological wards during the first and second phase of the pandemic agreed on a set of updated recommendations for current urology practice. Results: The updated recommendations…

2019-20 coronavirus outbreakmedicine.medical_specialtyCOVID-19 VaccinesCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Coronaviru030232 urology & nephrologycoronavirusmedicine.disease_causesurgery03 medical and health sciences0302 clinical medicinevaccinePandemicmedicineHumansOriginal Research Articlecoronavirus; COVID-19; pandemic; vaccine; urology; clinical practice guidelines; surgery; endourologyurologyPandemicsCoronavirusbusiness.industryImmunization ProgramsSARS-CoV-2pandemicendourologyCOVID-19General MedicineVirologySmart communication (SC173–SC181) Urinary stones: timing and assessmentVaccination030220 oncology & carcinogenesisEmergency medicineUrologic Surgical ProceduresCOVID-19; Coronavirus; clinical practice guidelines; endourology; pandemic; surgery; urology; vaccinebusinessclinical practice guidelinesclinical practice guideline
researchProduct

Immune biomarkers to predict SARS-CoV-2 vaccine effectiveness in patients with hematological malignancies

2021

AbstractThere is evidence of reduced SARS-CoV-2 vaccine effectiveness in patients with hematological malignancies. We hypothesized that tumor and treatment-related immunosuppression can be depicted in peripheral blood, and that immune profiling prior to vaccination can help predict immunogenicity. We performed a comprehensive immunological characterization of 83 hematological patients before vaccination and measured IgM, IgG, and IgA antibody response to four viral antigens at day +7 after second-dose COVID-19 vaccination using multidimensional and computational flow cytometry. Health care practitioners of similar age were the control group (n = 102). Forty-four out of 59 immune cell types …

AdultAged 80 and overMaleHaematological cancerCOVID-19 VaccinesSARS-CoV-2COVID-19Vaccine EfficacyNeoplasms. Tumors. Oncology. Including cancer and carcinogenslymphomaHematologyMiddle Agedhematologic malignancieArticleImmunocompromised HostmyelomaOncologyHematologic NeoplasmsHumansTumour immunologyFemaleSars-cov-BiomarkersRC254-282AgedBlood Cancer Journal
researchProduct

Sociodemographic and psychological correlates of COVID-19 vaccine hesitancy and resistance in the young adult population in Italy.

2021

Background: Previous research has shown that young adults are more hesitant/resistant to COVID-19 vaccine uptake than older age groups, although the factors underlying this tendency are still under debate. The current study aimed to identify the sociodemographic and psychological correlates of vaccine hesitancy and resistance among young adults (18–40 years) during the nationwide COVID-19 vaccination campaign in Italy, the first country after China being hit by the pandemic and which suffered a large number of fatalities. Methods: This is a cross-sectional, web-based study conducted in Italy using an ISO-certified international survey company (respondi.com). Data were collected on 1200 part…

AdultCOVID-19 VaccinesGeneral VeterinaryGeneral Immunology and MicrobiologySARS-CoV-2VaccinationPublic Health Environmental and Occupational HealthCOVID-19; Italy; Psychological correlates; Vaccine hesitancy; Young adults; Adult; Aged; Cross-Sectional Studies; Humans; SARS-CoV-2; Vaccination; Vaccination Hesitancy; Young Adult; COVID-19; COVID-19 VaccinesCOVID-19Settore M-PSI/04 - Psicologia Dello Sviluppo E Psicologia Dell'EducazioneYoung AdultInfectious DiseasesCross-Sectional StudiesItalyMolecular MedicinePsychological correlatesHumansVaccination HesitancySettore M-PSI/05 - Psicologia SocialeVaccine hesitancyYoung adultsAgedVaccine
researchProduct